vs
Side-by-side financial comparison of ASTRAZENECA PLC (AZN) and ENTERPRISE PRODUCTS PARTNERS L.P. (EPD). Click either name above to swap in a different company.
ASTRAZENECA PLC is the larger business by last-quarter revenue ($14.5B vs $14.4B, roughly 1.0× ENTERPRISE PRODUCTS PARTNERS L.P.). ASTRAZENECA PLC runs the higher net margin — 16.9% vs 10.4%, a 6.5% gap on every dollar of revenue. On growth, ASTRAZENECA PLC posted the faster year-over-year revenue change (11.7% vs -72.1%).
AstraZeneca plc (AZ) is a Swedish-British multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, UK. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation.
Enterprise Products Partners L.P. is an American midstream natural gas and crude oil pipeline company with headquarters in Houston, Texas. It acquired GulfTerra in September 2004. The company ranked No. 105 in the 2018 Fortune 500 list of the largest United States corporations by total revenue. Dan Duncan was the majority owner until his death in 2010.
AZN vs EPD — Head-to-Head
Income Statement — Q2 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $14.5B | $14.4B |
| Net Profit | $2.4B | $1.5B |
| Gross Margin | 82.9% | — |
| Operating Margin | 24.3% | 13.2% |
| Net Margin | 16.9% | 10.4% |
| Revenue YoY | 11.7% | -72.1% |
| Net Profit YoY | 27.0% | 6.4% |
| EPS (diluted) | $1.57 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $14.4B | ||
| Q4 25 | — | $13.8B | ||
| Q3 25 | — | $12.0B | ||
| Q2 25 | $14.5B | $11.4B | ||
| Q1 25 | — | $15.4B | ||
| Q4 24 | — | $14.2B | ||
| Q3 24 | — | $13.8B | ||
| Q2 24 | $12.9B | $13.5B |
| Q1 26 | — | $1.5B | ||
| Q4 25 | — | $1.6B | ||
| Q3 25 | — | $1.3B | ||
| Q2 25 | $2.4B | $1.4B | ||
| Q1 25 | — | $1.4B | ||
| Q4 24 | — | $1.6B | ||
| Q3 24 | — | $1.4B | ||
| Q2 24 | $1.9B | $1.4B |
| Q1 26 | — | — | ||
| Q4 25 | — | 27.0% | ||
| Q3 25 | — | 28.6% | ||
| Q2 25 | 82.9% | 30.5% | ||
| Q1 25 | — | 22.1% | ||
| Q4 24 | — | 25.3% | ||
| Q3 24 | — | 24.6% | ||
| Q2 24 | 83.1% | 24.5% |
| Q1 26 | — | 13.2% | ||
| Q4 25 | — | 14.7% | ||
| Q3 25 | — | 14.0% | ||
| Q2 25 | 24.3% | 15.8% | ||
| Q1 25 | — | 11.4% | ||
| Q4 24 | — | 13.9% | ||
| Q3 24 | — | 12.9% | ||
| Q2 24 | 21.2% | 13.1% |
| Q1 26 | — | 10.4% | ||
| Q4 25 | — | 11.9% | ||
| Q3 25 | — | 11.1% | ||
| Q2 25 | 16.9% | 12.6% | ||
| Q1 25 | — | 9.0% | ||
| Q4 24 | — | 11.4% | ||
| Q3 24 | — | 10.3% | ||
| Q2 24 | 14.9% | 10.4% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $1.57 | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $1.24 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $7.1B | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $44.8B | — |
| Total Assets | $112.4B | — |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $969.0M | ||
| Q3 25 | — | $206.0M | ||
| Q2 25 | $7.1B | $870.0M | ||
| Q1 25 | — | $220.0M | ||
| Q4 24 | — | $583.0M | ||
| Q3 24 | — | $1.4B | ||
| Q2 24 | $6.9B | $138.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $44.8B | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $39.6B | — |
| Q1 26 | — | — | ||
| Q4 25 | — | $77.9B | ||
| Q3 25 | — | $77.8B | ||
| Q2 25 | $112.4B | $77.4B | ||
| Q1 25 | — | $75.4B | ||
| Q4 24 | — | $77.2B | ||
| Q3 24 | — | $75.1B | ||
| Q2 24 | $104.3B | $73.6B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | — |
| Free Cash FlowOCF − Capex | — | $1.9B |
| FCF MarginFCF / Revenue | — | 13.4% |
| Capex IntensityCapex / Revenue | — | 1.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $2.5B | ||
| Q3 25 | — | $1.7B | ||
| Q2 25 | — | $2.1B | ||
| Q1 25 | — | $2.3B | ||
| Q4 24 | — | $2.4B | ||
| Q3 24 | — | $2.1B | ||
| Q2 24 | — | $1.6B |
| Q1 26 | — | $1.9B | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $762.0M | ||
| Q1 25 | — | $1.3B | ||
| Q4 24 | — | $1.3B | ||
| Q3 24 | — | $898.0M | ||
| Q2 24 | — | $310.0M |
| Q1 26 | — | 13.4% | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 6.7% | ||
| Q1 25 | — | 8.1% | ||
| Q4 24 | — | 9.1% | ||
| Q3 24 | — | 6.5% | ||
| Q2 24 | — | 2.3% |
| Q1 26 | — | 1.4% | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 11.4% | ||
| Q1 25 | — | 6.9% | ||
| Q4 24 | — | 7.5% | ||
| Q3 24 | — | 8.5% | ||
| Q2 24 | — | 9.4% |
| Q1 26 | — | — | ||
| Q4 25 | — | 1.50× | ||
| Q3 25 | — | 1.30× | ||
| Q2 25 | — | 1.44× | ||
| Q1 25 | — | 1.66× | ||
| Q4 24 | — | 1.46× | ||
| Q3 24 | — | 1.46× | ||
| Q2 24 | — | 1.12× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
